Primary progressive aphasia (PPA) is a rare neurological syndrome that gradually impairs a person’s language. Baycrest Canada ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 ...

Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the ...

A study has developed a reliable way to measure whether seriously ill hospitalized patients receive medical care that aligns ...

The CEO of GH Research, Dr. Velichka Valcheva, pointed out that the response addressed the FDA’s requests with comprehensive ...

The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile ...

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable ...

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

Rahway, New Jersey Wednesday, July 9, 2025, 13:00 Hrs [IST] ...

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PI ...

In the beginning, when I was very young, I was more interested in acute leukaemia and the suffering of young people. When I ...

Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 Diabetes ...